In an Investigator Initiated Study, competent national authorities require independence between the pharmaceutical company and the investigator. Ensuring that independence can be difficult when a study presents various and specific challenges for each party. Clinigen Clinical Supplies Management implemented a solution that would meet the specific needs of the study, meet the challenges faced by the pharmaceutical company, and provide the support required by the investigators.
Clinigen Clinical Supplies Management is currently supporting more than 100 IIS involving 13 different products from that same pharmaceutical company.
Read the case study to learn how our tailored solutions helped to minimize costs and product waste, all while ensuring independence of both parties.